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Abstract
Background: Adapter chimeric antigen receptor (CAR) approaches have emerged has promising strategies to
increase clinical safety of CAR T-cell therapy. In the UniCAR system, the safety switch is controlled via a target
module (TM) which is characterized by a small-size and short half-life. The rapid clearance of these TMs from the
blood allows a quick steering and self-limiting safety switch of UniCAR T-cells by TM dosing. This is mainly
important during onset of therapy when tumor burden and the risk for severe side effects are high. For long-term
UniCAR therapy, the continuous infusion of TMs may not be an optimal setting for the patients. Thus, in later stages
of treatment, single infusions of TMs with an increased half-life might play an important role in long-term
surveillance and eradication of residual tumor cells. Given this, we aimed to develop and characterize a novel TM
with extended half-life targeting the tumor-associated carbohydrate sialyl-Tn (STn).
Methods: The extended half-life TM is composed of the STn-specific single-chain variable fragment (scFv) and the
UniCAR epitope, fused to the hinge region and Fc domain of a human immunoglobulin 4 (IgG4) antibody. Specific
binding and functionality of the αSTn-IgG4 TM as well as pharmacokinetic features were assessed using in vitro and
in vivo assays and compared to the already established small-sized αSTn TM.
Results: The novel αSTn-IgG4 TM efficiently activates and redirects UniCAR T-cells to STn-expressing tumors in a
target-specific and TM-dependent manner, thereby promoting the secretion of proinflammatory cytokines and tumor
cell lysis in vitro and in experimental mice. Moreover, PET-imaging results demonstrate the specific enrichment of the
αSTn-IgG4 TM at the tumor site, while presenting a prolonged serum half-life compared to the short-lived αSTn TM.
Conclusion: In a clinical setting, the combination of TMs with different formats and pharmacokinetics may represent a
promising strategy for retargeting of UniCAR T-cells in a flexible, individualized and safe manner at particular stages of
therapy. Furthermore, as these molecules can be used for in vivo imaging, they pose as attractive candidates for
theranostic approaches.
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Background
CAR T-cell therapies are moving at a breakneck pace,
demonstrating remarkable clinical success particularly in
the treatment of blood malignancies [1]. Nevertheless,
some challenges still hinder their broad clinical applica-
tion, mainly related to on-target/off-tumor toxicity, cyto-
kine release syndrome and tumor escape variants [2–5].
Several approaches have been pursued in recent years,
aiming an increased safety by reducing the risk for these
recurrently reported side effects. Among them, the Uni-
CAR system developed by our group may fulfill the re-
quirements to improve specificity and safety of CAR T-
cell therapies [6]. In contrast to conventional CAR T-
cell approaches, UniCAR T-cells are not directed to a
tumor antigen but alternatively recognize the peptide
epitope E5B9. This epitope is derived from the nuclear
protein La/SS-B, which is not accessible on the surface
of intact living cells. UniCAR T-cells are therefore engi-
neered to express universal receptors composed of the
extracellular binding domain against the epitope E5B9,
the transmembrane domain derived from CD28 as well
as the intracellular signaling domains of CD28 and
CD3ζ. The cross-linkage between UniCAR effector cells
and target cells is mediated via a target module (TM)
composed of a binding moiety against a specific tumor
antigen fused to the E5B9 epitope (Fig. 1a) [7, 8]. This in
turn leads to the specific activation of the otherwise
inert UniCAR T-cells and allows a controlled on/off
switch of the UniCAR T-cells in case severe side effects
are observed. Furthermore, multiple targeting strategies
can be considered given that TMs can be easily con-
structed and interchanged using different formats and
specificities [8–12].
A repertoire of small-sized TMs directed against vari-
ous tumor-associated antigens has been developed in
our group. Given their short half-life, these TMs are rap-
idly eliminated from the blood [8–12], which allows a
quick control over UniCAR T-cell activity in case side
effects occur. Nonetheless, continuous administration is
required during therapy to maintain effective TM con-
centrations and perpetuate tumor cell killing by UniCAR
T-cells. Considering long-term treatment, a prolonged
activation of UniCAR T-cells to eradicate residual tumor
cells as well as reduction of TM infusions may be desir-
able for an improved therapeutic approach and patient
care at later phases of therapy. Therefore, in this work
we aimed to establish an extended half-life TM that
could present a promising tool for late-stage UniCAR T-
cell therapy while preserving the switchable safety fea-
tures of the UniCAR system. Within the collection of
small-sized TMs developed, a scFv-based TM directed
against the tumor-associated carbohydrate antigen sialyl-
Tn (STn) was proven to efficiently and specifically redir-
ect UniCAR T-cells to STn-expressing cancer cells [12].
Fig. 1 Illustrative representation of the UniCAR system and the αSTn-IgG4 TM construct. a The UniCAR system can be combined with different
TM formats, namely scFv- and IgG4-based TMs, to specifically redirect UniCAR T-cells to tumor cells via the E5B9 epitope. UniCAR T-cells are
genetically engineered to express the humanized scFv derived from the anti-La mAb 5B9 fused to the transmembrane domain of human CD28
and intracellular signaling domains of CD28 and CD3ζ. b Detailed representation of the αSTn-IgG4 TM construct, comprising the anti-STn scFv
(L2A5) arranged in VH - VL orientation linked by a (G4S)3 peptide, the hinge and Fc region of the human IgG4 molecule, and the E5B9 epitope.
After expression the αSTn-IgG4 TM will form homodimers due to formation of disulfide bridges between the cysteine residues present in the
IgG4 hinge region. c In order to confirm UniCAR expression, genetically modified T-cells were stained with isotype control (upper panel) or anti-
La mAb 7B6 (lower panel). Specific binding was detected using a PE-labeled anti-mouse-IgG mAb. Density plots show percentage of CAR surface
expression (E7B6) versus expression of co-translated EGFP protein marker for one representative donor. G, glycine; S, serine; A, alanine; P, proline;
C, cysteine
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This antigen is widely overexpressed in several types of
human carcinomas, such as gastric [13], colorectal [14],
ovarian [15], breast [16] and bladder [17] carcinomas.
Given that STn expression modulates a malignant
phenotype and is particularly associated with cancer ag-
gressiveness, metastasis and poor prognosis [18–20], in-
creasing attention has been recently drawn towards this
tumor antigen. Building upon this TM, a novel αSTn-
IgG4 TM based on the Fc region of immunoglobulin 4
(IgG4) antibodies was developed and assessed for its
capability to redirect UniCAR T-cells to STn-expressing
cancer cells both in vitro and in vivo.
Methods
Cell lines
STn expression is absent in the wild-type (WT) human
bladder cancer cell line MCR and in the WT human
breast cancer cell line MDA-MB-231 when cultured
in vitro. Therefore, MCR and MDA-MB-231 cell lines
expressing the STn antigen were generated as previously
reported [17, 21]. The murine 3T3 (ATCC CRL-1658)
fibroblast cells were used for production of αSTn and
αSTn-IgG4 TMs. Human embryonic kidney cells
HEK293T (ATCC CRL-11268) served as virus producing
cells. The MDA-MB-231 STn+ cell line was additionally
transduced with an open reading frame encoding the
firefly luciferase as previously described [22] and termed
MDA-MB-231 STn+ Luc. All cell lines were cultured in
Dulbecco’s modified Eagle medium (DMEM), supple-
mented with 10% (v/v) FBS, 2 mM L-glutamine, 100 U/
ml of penicillin and 100 μg/ml of streptomycin (Bio-
chrom) and maintained at 37°C in a humidified atmos-
phere of 5% CO2. For routine cell culture and in
preparation for experiments, cells were harvested from
the culture flasks using Trypsin-EDTA diluted in sterile
phosphate-buffered saline (PBS).
Construction, expression and purification of recombinant
antibodies
The αSTn TM was produced as described previously
[12]. For in silico construction of the αSTn-IgG4 TM,
the variable light (VL) and heavy (VH) chains of the
monoclonal antibody (mAb) L2A5 were arranged in a
VH-VL orientation and connected by a (Gly4Ser)3 linker.
The variable regions were further linked downstream to
the hinge and Fc region (CH2-CH3) derived from a hu-
man IgG4 antibody. The UniCAR tag (E5B9) followed
by a 6xHis tag was fused to the C-terminus of this mol-
ecule. An Igκ leader peptide (LP) sequence was fused to
the N-terminus to promote secretion of the TM into the
cell culture supernatant. The final sequence was cloned
into the vector p6NST50 and used for generation of
stable TM-producing 3T3 cell lines. Recombinant TMs
were purified from cell culture supernatant via protein A
affinity chromatography according to manufacturer’s in-
structions (Protein A HP Spin Trap, Sigma-Aldrich)
followed by overnight dialysis in PBS (Biochrom). Fi-
nally, SDS–PAGE and immunoblotting were used to as-
sess potential contaminants and to determine protein
concentration as previously described [23, 24].
Isolation, maintenance and lentiviral transduction of
human T-cells with UniCAR vectors
Primary human T-cells were isolated from peripheral
blood mononuclear cells (PBMCs) of buffy coats (sup-
plied by German Red Cross, Dresden, Germany), trans-
duced with UniCAR vectors, sorted and cultured as
described previously [23]. Cloning of UniCAR vectors
and production of UniCAR T-cells have been also de-
scribed before [23, 25]. UniCAR vectors include the
signaling UniCAR CD28/ζ construct, which contains the
co-stimulatory CD28 and activating CD3ζ domains; the
UniCAR Stop construct that lacks any intracellular sig-
naling domains; and the UniCAR vector control, encod-
ing only for the EGFP marker protein.
High-performance liquid chromatography
Purity of the purified TMs was assessed using size exclu-
sion high-performance liquid chromatography (SE-HPLC)
as described by Albert et al [10].
Flow-cytometry analysis
Specific binding of αSTn or αSTn-IgG4 TM to STn-
expressing cancer cells and respective equilibrium dis-
sociation constant (KD) values were determined using
flow cytometry. Shortly, 3×105 STn+ or WT (STn−) can-
cer cells were incubated for 1 h with 10 ng/μl or increas-
ing concentrations of TM, followed by a washing step
and subsequent incubation with mouse anti-La (5B9)
mAb for 30 min. Signal was detected using the PE-
conjugated goat anti-mouse IgG mAb (Beckmann
Coulter) after 30 min of incubation. In order to verify
UniCAR expression on the surface of T-cells, the pri-
mary anti-La mAb 7B6 and secondary PE-labeled goat
anti-mouse-IgG mAb (Beckmann Coulter) were used as
described previously [25]. All incubation steps were per-
formed at 4 °C in the dark. Stained cells were analyzed
using a MACSQuant® Analyzer and MACSQuantify®
software (Miltenyi Biotec). Based on the relative median
fluorescence intensity (MFI) of stained cells, a binding
curve was obtained and KD values were calculated using
the nonlinear regression curve fit (95% confidence inter-
val) with GraphPad Prism 7 software (GraphPad Soft-
ware Inc.).
Cytokine-release assay
To determine the levels of secreted cytokines, cell-free
supernatants from the co-culture of target cells and
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UniCAR T-cells in the presence or absence of TM were
harvest after 24 h incubation. Cytokine concentrations
were quantified using the MACSPlex Cytokine 12 Kit
(Miltenyi Biotec) according to the manufacturer’s
instructions.
Cell-mediated cytotoxicity assay
Cancer cell lysis mediated by UniCAR T-cells was
assessed in vitro by standard chromium-release assay
[26]. Briefly, 51Cr-labeled STn+ cancer cells were co-
cultured with the genetically modified UniCAR T-cells
in the presence or absence of TMs for 24 h. An effector
to target cell (E:T) ratio of 5:1 was used. Different con-
centrations of TM were applied to calculate the half
maximal effective concentration (EC50) value.
TM radiolabeling
All solvents were purchased from commercial sources
(Sigma−Aldrich, Fluka, VWR, Fisher Scientific). The no
carrier added (NCA) [64Cu]Cu2+ was produced at the
Helmholtz-Zentrum Dresden-Rossendorf on a TR-Flex
(Advanced Cyclotron Systems Inc.) by 64Ni(p,n)64Cu nu-
clear reaction and prepared as reported previously [27].
For labeling of the αSTn and αSTn-IgG4 TMs with
64Cu, [64Cu]CuCl2 (200MBq in 0.01M HCl, 0.3M
NH4OAc, pH 5.0) was added to 9.2 ± 6.7 nmol of the
TMs and tempered at 38 °C for 30 min. Labeling yield
and radiochemical purity were determined using radio
thin-layer chromatography (radio-ITLC). The radio-
ITLC was carried out on SG stripes (Merck) using 0.1M
citrate, 0.01M EDTA. The developed chromatograms
were analyzed by autoradiography using the In-vivo
Multispectral Imaging System (Bruker).
In vivo experiments using NOD-SCID mice and
bioluminescence imaging
Non-obese diabetic (NOD)-severe combined immune-
deficient (SCID) female mice at 6 weeks of age were pur-
chased from Janvier Labs (NOD.CB17-Prkdcscid/Rj). All
mice used throughout these experiments were healthy
and not involved in previous procedures. Health status
of mice was monitored daily by husbandry staff. Mice
were euthanized during experiment if they showed
hunched abnormal posture, impaired mobility, rough
coat, or paralysis. At the end of all experiments, animals
were euthanized using carbon dioxide inhalation and
cervical dislocation. All animal procedures were ap-
proved by the university committee for animal welfare.
To assess in vivo functionality of αSTn and αSTn-
IgG4 TMs, optical imaging analysis was performed in
which 0.5×106 UniCAR T-cells were mixed with 1×106
MDA-MB-231 STn+ Luc cells in the presence or ab-
sence of 300 pmol of αSTn or αSTn-IgG4 TM. The cor-
responding mixtures were subcutaneously injected in the
right flank of NOD-SCID mice. Mice were anesthetized
using 10% (v/v) desflurane (Baxter) and maintained with
8% (v/v) desflurane inhalation in 30% (v/v) oxygen in
order to perform luminescence imaging. Subsequently,
mice were injected intraperitoneally with 200 μL of D-
luciferin in PBS at a final concentration of 15 mg/ml
(Thermo Fisher Scientific). X-ray and luminescence im-
ages were acquired 5–10 min after luciferin injection.
Bioluminescence imaging was performed at day 0, 1 and
3 using In-vivo Multispectral Imaging System (Bruker).
Images were analyzed using the MI 5.3 and MS 1.3 soft-
ware (Bruker). Quantitative analysis was performed
assessing net luminescence intensities of the tumors
(photons/s/mm2).
Positron emission tomography (PET) imaging of tumor
xenograft models
PET imaging was performed to assess pharmacokinetics
and specific accumulation of radiolabeled αSTn TMs
([64Cu]Cu-NODAGA-αSTn and [64Cu]Cu-NODAGA-
αSTn-IgG4 TM) at the tumor site. Tumor induction was
achieved by subcutaneous injection of a suspension con-
taining 2×106 MDA-MB-231 STn+ Luc cells in PBS into
the right shoulder of the mice. Mice were kept under
the above-mentioned conditions for 2 to 3 weeks to
allow tumor growth. Thereafter, MDA-MB-231 STn+
Luc tumor-bearing mice were anesthetized as previously
described and 0.7 nmol of [64Cu]Cu-NODAGA-αSTn or
[64Cu]Cu-NODAGA-αSTn-IgG4 TM were intravenously
injected into a lateral tail vein of the mice. Imaging was
performed using dynamic scans acquired over 2 h with a
small animal PET scanner (microPET P4, Siemens) at
time point 0 h, and over 1 h at the time points 7, 20, 47
and 66 h after TM injection. Standard uptake values
(SUV) defined as tissue concentration (MBq/mL)/
injected dose (MBq)/body weight (g) in (g/ml) were used
to express activity concentrations. Images were visual-
ized and quantified using ROVER software (ABX).
Statistical analysis
Statistical significance was determined using GraphPad
Prism software 7.0 (GraphPad Software Inc.). Statistical
tests were specified in the respective figure legends. P
values below 0.05 were considered significant as follows:
*p < 0.1; **p < 0.01; ***p < 0.001 and ****p < 0.0001. All
error bars are represented either as standard error of the
mean (SEM) or standard deviation (SD).
Results
Construction of a novel IgG4-based TM targeting the STn
antigen
As previously described, UniCAR T-cells have been suc-
cessfully redirected using TMs with different formats,
such as nanobody- and scFv-based TMs, to target
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several tumor antigens [8–11]. In this work the possi-
bility of producing and using a TM with increased
size to redirect UniCAR T-cells was explored. Hence,
a novel IgG4-based TM format targeting STn was
constructed (Fig. 1). The structure of this construct is
similar to the scFv-based TM with the additional in-
sertion of the hinge and Fc (CH2-CH3) regions de-
rived from human IgG4 antibodies. These regions
were introduced between the binding domain (scFv)
derived from the αSTn mAb L2A5 [28] at the N-
terminus, and the E5B9 epitope used for UniCAR T-
cell recognition (Fig. 1b). A LP sequence was added
N-terminally to promote secretion of the TM into the
cell culture supernatant and a His-tag was fused at
the C-terminus to allow TM detection. The entire se-
quence encodes one polypeptide chain and given that
the cysteine residues present in the hinge region will
form disulfide bridges, a secreted homodimer com-
posed of two identical polypeptide chains is produced.
This molecule resembles the format of an IgG4 anti-
body and has a molecular weight (MW) of around
111 kDa, which is considerably increased compared to
a scFv-based TM (35 kDa). Additionally, and based on
the peptide tag E7B6 incorporated in the extracellular
part of the UniCAR, cell surface expression on T-
cells is routinely verified prior to performing the as-
says, as exemplified in Fig. 1c. Noteworthy, UniCAR
expression directly correlates with the expression of
co-translated EGFP marker protein.
Expression, purification and characterization of the αSTn-
IgG4 TM
The open reading frame of the αSTn-IgG4 TM was
cloned into the p6NST50 vector which was used for
transduction of murine 3T3 cells. The resulting cell line
served for production of the TM. Purification from cell
culture supernatants was performed using protein A
affinity chromatography. The purified αSTn-IgG4 TM
was analyzed by SDS-PAGE, immunoblotting and size
exclusion HPLC to confirm the correct molecular weight
and purity. Given that the purified STn-IgG4 TM forms
a homodimer, a MW of 111 kDa is calculated for this
molecule. However, due to the denaturing conditions of
the SDS-PAGE, the disulfide bridges within the hinge re-
gion are reduced and αSTn-IgG4 monomers are ex-
pected to be observed with a theoretical MW of 55 kDa.
As shown in both the SDS-PAGE and WB analyses, a
major band with a MW of around 60 kDa corresponding
to the αSTn-IgG4 monomers is observed (Fig. 2a and b).
Moreover, a faint band with a MW of around 130 kDa
was obtained, most likely representing the homodimeric
conformation of the αSTn-IgG4 TM. Size exclusion
HPLC was used to further confirm the purity and size of
the TM under native conditions. As expected, a major
peak with 89% of the total area was observed with a
MW of 143 kDa, corresponding to the homodimer
αSTn-IgG4 TM (Fig. 2c). Additionally, a minor peak
(11% of the total area) was obtained at a MW of 254
kDa, which suggests the presence of αSTn-IgG4
Fig. 2 Analysis of purified αSTn-IgG4 TM by SDS-PAGE, Western Blot and size exclusion HPLC. The αSTn-IgG4 TM was purified from the supernatant of
TM-producing 3T3 cells using protein A columns. The dialyzed TM was resolved by SDS-PAGE and stained with (a) Coomassie Brilliant Blue G250 or (b)
analyzed by WB using αHis mAb for detection of the C-terminus His-tag. c Chromatogram obtained by size exclusion HPLC of 10 μg of purified TM
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oligomers or possible contaminants (Fig. 2c). Collect-
ively, these results demonstrate the successful produc-
tion and purification of the homodimeric αSTn-IgG4
TM with high purity for further in vitro and in vivo
functional characterization.
Binding and affinity assessment of the αSTn-IgG4 TM
The first feature assessed was the capacity of the novel
αSTn-IgG4 TM to specifically bind to STn-expressing
cancer cells. This was done by flow cytometry using the
breast cancer cell line MDA-MB-231 STn+ and the blad-
der carcinoma cell line MCR STn+. The parental anti-
body L2A5 mAb and the scFv-based TM (αSTn TM)
were used as positive controls. As represented in Fig. 3a,
αSTn-IgG4 TM has a comparable binding pattern to
both positive controls. Additionally, no binding was ob-
served when performing an equivalent staining on the
corresponding cancer cell lines lacking the expression of
STn (WT cell lines) (Fig. S1). Binding affinity curves of
both αSTn TMs were obtained for STn-expressing cell
lines by TM titration (Fig. 3b and c). Affinity binding
values (KD values) of around 4 nM were obtained for the
αSTn-IgG4 TM, in contrast to 57 and 75 nM determined
for the αSTn TM. This observation further corroborates
the principle that more binding valences increase the
binding strength of antibody derivatives. As the αSTn-
IgG4 TM has two αSTn binding arms in comparison to
the monovalent αSTn TM, it binds more effectively to
STn-expressing tumor cells. The acquired data addition-
ally show that after binding of the TM to the target anti-
gen, the UniCAR tag (E5B9 epitope) is still accessible for
recognition by the αE5B9 UniCAR domain, which is an
important requirement for successful interaction with
UniCAR T-cells. Overall, these results demonstrate that
the αSTn-IgG4 TM is able to specifically bind its target
antigen on the surface of different cancer cell lines with
an increased binding affinity in comparison to the previ-
ously designed αSTn TM.
Engagement via αSTn-IgG4 TM leads to specific lysis of
STn+ tumor cells by UniCAR T-cells
After confirming the specific binding of the αSTn-IgG4
TM to STn-expressing cancer cells, functionality regard-
ing in vitro killing efficiency was assessed using chro-
mium release assays. For that, human T-cells from
healthy donors were transduced with lentiviral vectors
encoding either the UniCAR sequence comprising an
intracellular signaling domain (UniCAR 28/ζ), the Uni-
CAR sequence lacking any signaling domains (UniCAR
Stop) or the EGFP marker protein alone (vector control).
Fig. 3 Binding of αSTn and αSTn-IgG4 TMs to STn-expressing cancer cells. a Both MDA-MB-231 and MCR cancer cells expressing STn were stained
with 1 μg of TMs, mAb 5B9 and PE-labeled anti-mouse-IgG mAb. Staining with αSTn mAbs L2A5 and αSTn TM served as positive controls. L2A5 mAb
was detected using an Alexa Fluor 488 anti-mouse IgM mAb. Stained cells (black lines) and respective controls (grey lines) are displayed as
histograms. MFI and percentage of positively stained cells (in parenthesis) are shown. Results for one representative binding assay are depicted. b
and c Binding affinity curves of αSTn (grey) or αSTn-IgG4 (black) TMs to MDA-MB-231 STn+ (b) and MCR STn+ (c) cells were obtained using increasing
concentrations of TM. Binding was detected as described above. Data are presented as MFI average values ± SD from four independent experiments
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UniCAR Stop and vector control T-cells served as nega-
tive controls. Chromium release was measured 24 h after
co-culture of STn-expressing cancer cells with trans-
duced T-cells at an E:T ratio of 5:1 in the presence or
absence of αSTn-IgG4 TM or αSTn TM. As shown in
Fig. 4a and b, both TMs induce efficient lysis of STn-
expressing tumor cells by UniCAR 28/ζ T-cells. Contrar-
ily, UniCAR T-cells were not able to eradicate tumor
cells in the absence of TM. As expected, UniCAR Stop
and vector control T-cells were completely inert in the
presence or absence of TM. Using a similar assay set up,
the αSTn-IgG4 TM was titrated in order to calculate the
EC50. As represented in Fig. 4c and d, EC50 values of 0.4
nM and 0.1 nM were determined for MDA-MB-231
STn+ and MCR STn+ cells using the αSTn-IgG4 TM, re-
spectively. In comparison to the αSTn TM (12.2 nM and
25.0 nM), a lower concentration of αSTn-IgG4 TM was
sufficient to achieve a similar maximal tumor cell lysis.
Most likely, the increased avidity results in higher killing
efficiency of the αSTn-IgG4 TM. Taken together, these
data show that UniCAR T-cells can be redirected using
an IgG4-based TM to specifically target STn-expressing
cancer cells with increased efficiency.
UniCAR T-cells redirected by the αSTn-IgG4 TM promote
the release of proinflammatory cytokines
Having substantiated the TM-mediated killing capacity
of UniCAR T-cells upon cross-linkage to STn-
expressing tumor cells using the αSTn-IgG4 TM, the
cytokine release pattern of UniCAR T-cells was assessed.
For that, UniCAR T-cells were incubated in the presence
or absence of MDA-MB-231 STn+ (Fig. 5a) or MCR
STn+ (Fig. 5b) cells, with or without the αSTn or αSTn-
IgG4 TMs. After 24 h of incubation, the concentration
of cytokines present in cell-free culture supernatants was
analyzed using a multiplex assay (MACSPlex Cytokine
12 Kit). In this assay, detection and quantification of the
cytokines TNF-α, IFN-γ, IFN-α, GM-CSF, IL-2, IL-4, IL-
5, IL-6, IL-9, IL-10, IL-12 and IL-17A are performed
simultaneously. Significant cytokine concentrations were
detected for TNF-α, IFN-γ, GM-CSF and IL-6 (Fig. 5).
Except for IL-6, all of these cytokines were specifically
detected only in co-cultures of UniCAR T-cells with
STn+ cancer cells in the presence of αSTn or αSTn-
IgG4 TMs, with a significantly higher amount of se-
creted cytokines for the αSTn-IgG4 TM in comparison
to the αSTn TM. Nevertheless, IL-6 was detected in all
Fig. 4 Cytotoxic potential of retargeted UniCAR T-cells via αSTn-IgG4 TM. Killing of MDA-MB-231 STn+ (b) and MCR STn+ (a), was determined
using standard chromium release assay. Chromium-labeled STn-expressing cell lines were incubated with control T-cells (vector control and
UniCAR Stop) or UniCAR 28/ζ T-cells for 24 h at an E:T ratio of 5:1, in the presence or absence of 10 pmol αSTn TM and αSTn-IgG4 TM. c and d
Following a similar experimental setup using increasing TM concentrations, half maximal effective concentration (EC50) was determined from the
resulting dose-response curves using MDA-MB-231 STn+ (c) and MCR STn+ (d) cells. Data for three individual donors were summarized as mean
specific lysis ± SD. Statistical significance was obtained using 2-way ANOVA with Bonferroni multiple-comparison test (****p < 0.0001, with respect
to w/o TM experimental setting)
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conditions that include cancer cells, suggesting that IL-6
is intrinsically secreted by the STn-expressing cancer cell
lines used. This is in accordance with similar results pre-
viously observed for the αSTn TM using the same cell
lines [12]. Importantly, none of the tested cytokines were
present in supernatants recovered from negative control
UniCAR T-cells (UniCAR Stop and vector control) or
from UniCAR T-cells in the absence of TM and cancer
cells (Fig. S2). Overall, the release of proinflammatory
cytokines was specifically observed for the combination
of UniCAR T-cells in the presence of target cancer cells
and αSTn-IgG4 TM.
Efficient and TM-dependent inhibition of tumor growth in
experimental mice by UniCAR T-cells redirected with the
αSTn-IgG4 TM
Once killing efficiency was validated in vitro, the in vivo
anti-tumor activity of UniCAR T-cells retargeted via the
αSTn-IgG4 TM was analyzed using a xenograft tumor
mouse model. For that, MDA-MB-231 STn+ cells trans-
duced with luciferase (MDA-MB-231 STn+ Luc cells)
were required to allow tumor imaging and follow-up
during the experiment. Consequently, five groups of
NOD-SCID mice were created. Three groups were
injected subcutaneously with MDA-MB-231 STn+ Luc
cells alone, MDA-MB-231 STn+ Luc cells with αSTn-
IgG4 TM or MDA-MB-231 STn+ Luc cells with Uni-
CAR T-cells, serving as controls. For the two treatment
groups, MDA-MB-231 STn+ Luc cells with UniCAR T-
cells and αSTn TM or αSTn-IgG4 TM were injected.
Tumor growth was monitored over 3 days by biolumin-
escence imaging. Qualitative imaging and corresponding
quantitative results are shown in Fig. 6a and b, respect-
ively. Corroborating the in vitro data, injection of STn+
target cells with UniCAR 28/ζ T-cells and αSTn or
αSTn-IgG4 TMs significantly inhibited tumor growth
already 1 day after injection. Absence of tumors was fur-
ther verified up to 3 days after injection. Conversely and
as expected for the control groups, injection of UniCAR
T-cells or αSTn-IgG4 TM alone did not hinder tumor
growth. The quantitative analysis of the imaging results
reveals an increased killing potential of αSTn-IgG4-
redirected UniCAR T-cells compared to the αSTn TM,
represented by a more pronounced decrease in tumor
bioluminescence intensity obtained upon injection of the
αSTn-IgG4 TM (Fig. 6b). These results demonstrate the
effective and TM-dependent eradication of STn-
expressing tumors by redirected UniCAR T-cells in vivo,
with significant inhibition of tumor growth using the
αSTn-IgG4 TM.
Fig. 5 Proinflammatory cytokine secretion profile of UniCAR T-cells redirected via αSTn and αSTn-IgG4 TMs. T-cells transduced with UniCAR 28/ζ
constructs were co-cultured with MDA-MB-231 STn+ (a) or MCR STn+ (b) in the presence or absence of αSTn or αSTn-IgG4 TMs at an E:T ratio of
5:1. After incubation for 24 h, cell culture supernatants were harvested and analyzed using the MACSPlex Cytokine 12 kit. Average cytokine
concentrations and SD for three individual donors are shown. Statistical significance was determined using 1-way ANOVA with Bonferroni
multiple-comparison test (*p < 0.05; **p < 0.01)
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Kinetics and PET imaging of the αSTn-IgG4 TM in mice
bearing STn+ tumors
To evaluate the pharmacokinetics of the radiolabeled
αSTn-IgG4 TM for in vivo imaging of STn-
overexpressing tumor sites, the αSTn-IgG4 TM was con-
jugated with the chelator NODAGA and further labeled
with the PET isotope copper resulting in [64Cu]Cu-
NODAGA-αSTn-IgG4 TM. A labeling yield and radio-
chemical purity (decay-corrected) of 94 ± 5% was deter-
mined by radio-ITLC. Furthermore, a molar activity of
11 ± 8 GBq/μmol was obtained. For comparison, the
αSTn TM was conjugated with NODAGA and labeled
with copper following a similar protocol. To perform
small animal PET, MDA-MB-231 STn+ Luc tumors were
established on the right shoulder of NOD-SCID mice 2
weeks prior to injection of the radiolabeled TMs. Fig-
ure 7a summarizes accumulation at the tumor site and
clearance of the [64Cu]Cu-NODAGA-αSTn-IgG4 TM
over 3 days. As shown, a maximum accumulation at the
tumor site was observed around 46 h after injection with
a slow blood clearance between 50 to 66 h (Fig. 7a and
b). These data indicate that the αSTn-IgG4 TM has a
delayed maximum accumulation at the tumor compared
to the αSTn scFv-based TM (around 2 h). Additionally, a
longer lasting accumulation is obtained in contrast to
the scFv-based TM. Furthermore, time activity curves of
the dynamic PET analysis of blood were used to deter-
mine serum half-life (Fig. 7c). Based on the values of the
area-under-curve obtained for the [64Cu]Cu-NODAGA-
αSTn TM and [64Cu]Cu-NODAGA-αSTn-IgG4 TM
(40.3 and 200.2, respectively), blood half-life values of
1.2 h for the αSTn TM and 12 h for the αSTn-IgG4 TM
were calculated. In summary, the obtained results dem-
onstrate a specific and long-lasting accumulation of the
αSTn-IgG4 TM at the tumor site in accordance with its
extended half-life.
Discussion
Recently, switchable adapter CAR T-cell platforms have
been established to circumvent the main hurdles of con-
ventional CAR T-cell therapies [5]. Thereby, activity of
CAR T-cells is controlled based on the specificity, size,
molecular design and pharmacokinetics of the selected
CAR adaptor. Our group established the modular
UniCAR platform, in which various TMs with short
half-life targeting different tumor-associated antigens
have been demonstrated to redirect UniCAR T-cells to
specifically eradicate tumor cells [8–12]. As a key
Fig. 6 In vivo killing capacity of redirected UniCAR T-cells in NOD-SCID mice using αSTn-IgG4 and αSTn TMs. Five groups composed of five NOD-
SCID mice were established, from which mice injected with MDA-MB-231 STn+ Luc tumor cells alone; tumor cells mixed with αSTn-IgG4 TM or
tumor cells mixed with UniCAR 28/ζ T-cells were used as negative controls. Mice co-injected with tumor cells, UniCAR 28/ζ T-cells and αSTn TM
or αSTn-IgG4 TM were used as treatment groups. All injections were performed subcutaneously into the right hind flank. a Bioluminescence
imaging of anesthetized mice was performed at day 0, 1 and 3. b Based on the luminescence imaging results obtained, a quantitative analysis
was performed. The values were normalized to the initial measurement performed after injection on day 0 and represented as mean ± SEM.
Statistical significance was determined using two-way ANOVA with Bonferroni multiple-comparison test with respect to the control group
injected with MDA-MB-231 STn+ Luc and UniCAR 28/ζ T-cells (*p < 0.1; **p < 0.01; ***p < 0.001)
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prerequisite of the UniCAR system, TMs should be rap-
idly eliminated from the peripheral blood to provide a
quick steering and self-limiting safety switch in case se-
vere side effects arise. Consequently, activation and po-
tential adverse effects of UniCAR T-cells can be easily
tuned by dosing TM infusions. To overcome the con-
tinuous infusion required for such small-sized TMs at
later stages of therapy, we developed an extended half-
life TM targeting the STn antigen based on the back-
bone of human IgG4 antibodies. For that, the scFv de-
rived from the mAb L2A5 and the E5B9 epitope were
fused to the human IgG4 hinge and Fc region. The back-
bone of the IgG4 molecule was chosen due to the lim-
ited binding to Fc receptors as well as the weak or
absent activation of both complement and antibody-
dependent cellular cytotoxicity [29]. As a result, IgG4
antibodies have been widely used to design therapeutic
antibodies when a weak or absent immune cell activa-
tion is desired, yet maintaining an increased plasmatic
half-life comparable to the other IgG subclasses [30].
We successfully produced a homodimeric αSTn-IgG4
TM with considerably high purity that specifically binds
to STn-expressing cancer cell lines and promotes effi-
cient tumor cell lysis by redirected UniCAR T-cells both
in vitro and in experimental mice. Both scFv-based and
IgG4-based TMs bind to STn+ cancer cells with high af-
finity. Bearing in mind that the underlying anti-STn
mAb L2A5 is a dekavalent IgM mAb [28], the high cal-
culated affinities of these TMs were surprising. Compar-
ing both TMs, a 12 to 17-fold increase in binding
affinity was obtained for the αSTn-IgG4 TM (4 nM com-
pared to 57 nM and 75 nM). This result can be mainly
explained by the fact that the αSTn-IgG4 TM has two
binding sites in contrast to the monovalent αSTn TM.
Furthermore, lower amounts of IgG4-based TM were re-
quired to obtain similar specific cell lysis compared to
the scFv-based TM. This may again be explained due to
the geometry and valency of the αSTn-IgG4 TM. Em-
phasis should also be placed to the importance of the
distance and molecular geometry of the immunological
synapse to ensure adequate activation of effector cell
functions. Previous studies using conventional CARs
have reported attenuated activation signaling due to the
formation of longer immunological synapses and varia-
tions in the antigen location and density on target cells
[31, 32]. Interestingly, recent reports highlight the effect-
ive formation of the immunological synapse and conse-
quent T cell activation using different modular CAR
formats, demonstrating a surprising plasticity and vari-
ability of such approaches [3, 33, 34]. Here, we demon-
strate that the immunological synapse formed by the
large αSTn-IgG4 TMs does not affect the activation nor
cytotoxic potential of UniCAR T-cells targeting the STn
antigen. This validates the versatility of the UniCAR
Fig. 7 PET analysis of STn+ tumor-bearing mouse injected with [64Cu]Cu-NODAGA-αSTn-IgG4 TM. The TMs were conjugated with NODAGA,
labeled with copper-64 (64Cu) and injected as a single bolus intravenously into NOD-SCID mice bearing established MDA-MB-231 STn+ Luc
tumors. a Representative coronal view of the maximum intensity projection (MIP) of the [64Cu]Cu-NODAGA-αSTn-IgG4 TM distribution after 2, 7,
20, 47 and 66 h. Tumor is highlighted by yellow circles. b Time activity curves (TAC) of the dynamic PET analysis of regions of interest (ROI)
obtained using the radiolabeled αSTn-IgG4 TM for blood, tumor and muscle. c Comparative view of blood TAC for the αSTn-IgG4 (red curve) and
αSTn TMs (blue curve) over 66 h. SUV, standard uptake values
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system, which can be easily combined with TM formats
of different sizes and designs without hampering Uni-
CAR T-cell activation and killing efficiency. Accordingly,
upon TM-mediated cancer cell lysis, UniCAR T-cells se-
creted the cytokines TNF-α, IFN-γ, GM-CSF and IL-2.
Worth mentioning, IL-6, which is mainly held respon-
sible for cytokine release syndrome, was detected in su-
pernatants of samples containing target cells regardless
of the presence or absence of the αSTn-IgG4 TM. This
suggests that IL-6 is released by MDA-MB-231 and
MCR cancer cells and not by activated UniCAR T-cells,
which is in line with our previous publication and other
studies [12, 35, 36]. As stated before, proinflammatory
cytokines are specifically released following TM-
dependent cross-linkage of tumor and UniCAR T-cells.
TNF-α, IFN-γ and GM-CSF are known to be involved in
mechanisms such as induction of tumor cell apoptosis
as well as proliferation and activation of T-cells. The
aforementioned cytokines can further stimulate other
immune cells to overcome the immunosuppressive
microenvironment often seen in solid cancers, including
STn+ tumors [37]. Moreover, STn has been recently re-
ported to be expressed on the surface of infiltrating mye-
loid derived suppressor cells (MDSCs) [37]. Hence, in a
clinical setting eradication of STn-expressing tumors via
redirected UniCAR T-cells may be augmented by the
additional depletion of immune-suppressive MDSCs,
which subsequently endorses immune re-engagement.
PET imaging results show a specific enrichment of the
αSTn-IgG4 TM at the tumor site with maximum accu-
mulation at around 46 h after injection and a slow clear-
ance between 50 to 66 h. Furthermore, dynamic PET
analysis emphasizes the extended blood half-life of 12 h
for the αSTn-IgG4 TM compared to approximately 1 h
obtained for the αSTn TM. These properties of the
αSTn-IgG4 TM are mainly related to its increased mo-
lecular weight, which leads to a delayed but prolonged
accumulation at the tumor, additionally preventing its
rapid clearance via the kidneys. FcRn-mediated recycling
may also play a role and affect the lifespan of the αSTn-
IgG4 TM, increasing the retention time of this molecule
in the plasma [38]. In light of future clinical applications,
combination of small-sized and extended half-life TMs
with UniCAR T-cells might allow a more convenient
treatment regimen for cancer patients. During onset of
therapy when tumor burden is high, an scFv-based TM
should be continuously applied to enable a rapid off-
switch of UniCAR T-cells by ceasing TM infusion in
case of unwanted toxicities. In later stages of therapy,
when tumor burden is lower and thus side effects are
less likely to occur, the use of a TM with extended half-
life may be important to reduce the number of infusions
as well as to enhance eradication of residual tumor cells.
Such an approach may be particularly relevant when
targeting STn-expressing tumors, as STn expression is
frequently associated with tumor invasiveness, metastasis
and immune escape, especially in breast and bladder
cancer [17, 39–41]. Even though the blood clearance of
the IgG4-based TM is considerably delayed, the safety
profile is not compromised since the TM would be elim-
inated at some point and therefore, a controlled inactiva-
tion of UniCAR T-cells would be achieved. In this way,
the risk to develop long-term side effects caused by con-
tinuously activated conventional CAR T-cells would still
be minimized.
The pharmacokinetic features and stable accumulation
of radiolabeled αSTn-IgG4 TMs at the tumor site com-
bined with the possibility to simultaneously redirect Uni-
CAR T-cells to eradicate tumor cells further highlights
its potential application for theranostic purposes. Thus,
therapy and tumor imaging could be combined in a sin-
gle radiolabeled TM aiming at a patient-centered care.
Depending on the selected radionuclide, the modified
TM might be routinely used for PET/CT imaging or
endoradiotherapy. In that way, the radiolabeled αSTn-
IgG4 TM could be used as a tracer for diagnosis and
monitoring of tumor diseases while enabling simultan-
eous immunotherapy with the UniCAR system. Yet, add-
itional work and validation are required in this regard.
Conclusions
Taken together, a novel IgG4-based TM with extended
half-life targeting the STn antigen has been developed
and proven to efficiently redirect UniCAR T-cells to
STn-expressing cancer cells in a highly target-specific
manner both in vitro and in vivo. Thereby, the UniCAR
T-cell technology can be used in a customized way, in
which TMs with different pharmacokinetic features, and
if required with different specificities, can be adminis-
tered according to the stage and demands observed dur-
ing cancer therapy. Contrarily to the current
conventional CAR T-cell therapies, this type of tailored
approach would provide a more convenient and control-
lable way to treat patients according to the therapy stage
and response to treatment. Furthermore, radiolabeled
TMs may be attractive candidates for diagnostics and
therapy monitoring. Their high potential for theranostic
applications fosters the transition from conventional to
personalized medicine.
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Supplementary information accompanies this paper at https://doi.org/10.
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Additional file 1: Figure S1. Binding of αSTn and αSTn-IgG4 TMs to
MDA-MB-231 and MCR wild-type (WT) cancer cells. Both MDA-MB-231
and MCR WT cancer cells were stained with 1 μg of TMs, mAb 5B9 and
PE-labeled anti-mouse-IgG mAb. The αSTn L2A5 mAb was detected using
an Alexa Fluor 488 anti-mouse IgM mAb. Stained cells (black lines) and
Loureiro et al. Journal of Experimental & Clinical Cancer Research           (2020) 39:77 Page 11 of 13
respective isotype controls (grey lines) are displayed as histograms. MFI
values are shown. Results for one representative binding assay are shown.
Figure S2. Cross-linkage of UniCAR T-cells with STn+ tumor cells via
αSTn-IgG4 TM results in release of cytokines. In a 24 h-cytokine-release
assay, (a) MDA-MB-231 STn+ or (b) MCR STn+ cells were incubated with
vector control, UniCAR Stop or UniCAR 28/ζ T-cells in the presence or ab-
sence of αSTn-IgG4 TM (E:T ratio of 5:1). Cytokine concentrations in cell-
free co-culture supernatants were detected using the MACSPlex Cytokine
12 kit. Average cytokine concentrations and SD for three individual do-
nors are shown. Statistical significance was determined using 2-way
ANOVA with Bonferroni multiple-comparison test (**p < 0.01; ***p < 0.001
and ****p < 0.0001).
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